Pharmacist-Led Care for Cardiovascular Disease
(INCLUDE Trial)

Recruiting in Palo Alto (17 mi)

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Academic

Waitlist Available

Sponsor: Intermountain Health Care, Inc.

No Placebo Group

Trial Summary

What is the purpose of this trial?Patients who had an ASCVD event at an Intermountain hospital will be screened for eligibility to be randomized. Subjects who meet eligibility criteria will be randomized 1:1 to receive targeted care of their LDL-C through a pharmacist-driven management program or not. Patients may opt-out of receiving LDL-C management by the pharmacy team at any time. The purpose of this program is to increase the proportion of patients who achieve guideline-based recommendations of LDL-C levels of \<70 mg/dL by increasing statin and/or LLT adherence and LDL-C testing. Data collection as part of the study will continue until the last person randomized has had 1-year of follow-up.

Eligibility Criteria

This trial is for patients who have had an event related to atherosclerotic cardiovascular disease at an Intermountain hospital. They should be willing to potentially receive LDL-C management from a clinical pharmacy team and follow up for one year.

Inclusion Criteria

Value-based patient (as defined in the EDW)

I am over 18 years old.

Receives follow-up care with Intermountain Health

+1 more

Exclusion Criteria

Pregnant or lactating women

I am receiving or will receive care to ease symptoms, not cure my disease.

I am under 18 years old.

Participant Groups

The study compares two approaches: one where patients get targeted care for managing their LDL cholesterol through a pharmacist-led program, versus usual care without this specialized intervention. The goal is to see if the pharmacy program helps more people reach ideal LDL levels.

2Treatment groups

Experimental Treatment

Active Control

Group I: Clinical Pharmacy TeamExperimental Treatment1 Intervention

Patients will receive targeted care of their LDL-C through a pharmacist-driven management program.

Group II: Usual CareActive Control1 Intervention

Patients will receive usual care for their LDL-C management.